YTEN - Yield10 Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8755
-0.0245 (-2.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9000
Open0.8800
Bid0.8400 x 3000
Ask0.9100 x 1400
Day's Range0.8150 - 0.8800
52 Week Range0.6800 - 1.8500
Volume100,728
Avg. Volume198,277
Market Cap10.939M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.9030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Yield10 Bioscience Announces First Quarter 2019 Financial Results

    WOBURN, Mass., May 09, 2019 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for.

  • GlobeNewswire16 days ago

    Yield10 Bioscience Signs Exclusive Worldwide License with University of Missouri for Advanced Technology Used to Boost Oil Content in Crops

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has signed an exclusive worldwide license from the University of Missouri (MU) for a novel, advanced technology to boost oil content in crops. The license expands Yield10’s intellectual property portfolio around technologies for increasing oil content in oilseed crops. This new gene target, designated C3012 by Yield10, is consistent with the Company’s focus on using CRISPR-Cas/9 genome-editing to increase seed oil content, the primary economic value driver in these crops.

  • American City Business Journals17 days ago

    These are the highest paid tech CEOs in Massachusetts

    The Boston Business Journal’s ranking of the highest paid tech CEOs is a look at 25 chief executives' total compensation in Massachusetts companies, based on information from proxy statements filed with the Securities and Exchange Commission in spring of this year.

  • GlobeNewswire23 days ago

    Yield10 Bioscience to Announce First Quarter 2019 Financial Results and Host a Conference Call on Thursday, May 9, 2019

    Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that the Company will report its first quarter 2019 financial results and provide a corporate update on Thursday, May 9, 2019. International callers should call +1-201-689-8354. The call will also be available through a live webcast, and will reference a slide deck which may be accessed through the investor relations section of the Company’s website at www.yield10bio.com.

  • GlobeNewswirelast month

    Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C3003

    The Notice of Allowance relates to U.S. patent application No. 2016/032,6541 entitled “Plants with enhanced photosynthesis and methods of manufacture thereof.” Yield10 is the exclusive licensee of this intellectual property from The University of Massachusetts. The C3003 yield trait is based on a transporter gene derived from algae that can be used to increase seed yield in plants.

  • Woburn agri-biotech Yield10 needs to secure extra funds to continue operations
    American City Business Journalslast month

    Woburn agri-biotech Yield10 needs to secure extra funds to continue operations

    Woburn-based agricultural bioscience company Yield10 needs to secure funding to make it through the year, according to the company’s public filings, and it’s considering different ways to bring in additional capital, the CEO told the Boston Business Journal.

  • The Zacks Analyst Blog Highlights: MGP Ingredients, Medifast, Ubiquiti Networks, Yield10 Bioscience and Otter Tail
    Zackslast month

    The Zacks Analyst Blog Highlights: MGP Ingredients, Medifast, Ubiquiti Networks, Yield10 Bioscience and Otter Tail

    The Zacks Analyst Blog Highlights: MGP Ingredients, Medifast, Ubiquiti Networks, Yield10 Bioscience and Otter Tail

  • Global Economic Growth Concerns Resurface: 5 Safe Picks
    Zackslast month

    Global Economic Growth Concerns Resurface: 5 Safe Picks

    Concerns over slowing global growth have contributed to this uncertainty and dented investors' confidence to some extent.

  • GlobeNewswire2 months ago

    Yield10 Bioscience CEO Oliver Peoples to Present at the Advanced Bioeconomy Leadership Conference on April 3, 2019

    Dr. Peoples’ presentation is titled “The Yield10 Trait Factory: Deploying Knowledge Gained from Industrial Biotech with Genome-editing to Increase Crop Yield” and will take place on the ABLC Advanced Nutrition & Bioeconomy Feedstocks and Supply Chain track in a panel entitled “Advanced Yields through Technology” on Wednesday April 3, 2019 at 12:40 p.m. Eastern Time. Dr. Peoples will describe the approaches Yield10 is taking to increase seed yield, oil content and biomass in crops.

  • GuruFocus.com2 months ago

    Yield10 Bioscience Inc (YTEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Yield10 Bioscience Inc, formerly known as Metabolix Inc is an agricultural bioscience company. Yield10 Bioscience Inc had annual average EBITDA growth of 54.90% over the past five years. Warning! GuruFocus has detected 5 Warning Signs with YTEN.

  • GlobeNewswire2 months ago

    Yield10 Bioscience Announces Fourth Quarter and Full Year 2018 Financial Results

    WOBURN, Mass., March 25, 2019 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for.

  • GlobeNewswire2 months ago

    Yield10 Bioscience to Present at the Spring Investor Summit on April 2, 2019

    Yield10 Bioscience, Inc. (YTEN) today announced that Oliver Peoples, Ph.D., president and chief executive officer of Yield10 will be a featured presenter at the Spring Investor Summit on Tuesday, April 2, 2019 at 10:30 a.m. EDT. Dr. Peoples will provide an overview of the Company’s business model and growth strategy and will be available for one-on-one meetings. A live webcast of the corporate presentation will be available on the Company's website at  www.yield10bio.com.  A replay of the presentation will be available for 90 days.

  • GlobeNewswire2 months ago

    Yield10 Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on Monday, March 25, 2019, at 4:30 p.m. EDT

    WOBURN, Mass. , March 19, 2019 -- Yield10 Bioscience, Inc. (NASDAQ: YTEN) announced today that the Company will report its fourth quarter and full year 2018 financial results.

  • GlobeNewswire2 months ago

    Yield10 Bioscience Announces Pricing of $2.9 Million Registered Direct Offering

    Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced that it has entered into a securities purchase agreement with certain institutional investors and existing investor Jack W. Schuler, providing for the purchase and sale of 2,421,662 shares of common stock at $1.2101 per share in a registered direct offering, resulting in total gross proceeds of approximately $2.9 million. The price per share was equal to the closing price of the common stock on the Nasdaq Capital Market on March 13, 2019. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American:LTS) is acting as exclusive placement agent for the registered direct offering.

  • Do Directors Own Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?
    Simply Wall St.3 months ago

    Do Directors Own Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?

    A look at the shareholders of Yield10 Bioscience, Inc. (NASDAQ:YTEN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusualRead More...

  • GlobeNewswire4 months ago

    Yield10 Bioscience Initiates Early Development Program in Corn to Evaluate Novel Traits

    Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, announced today that it has initiated an early development program in corn to evaluate novel seed yield and drought tolerance traits. Corn is the highest value commercial row crop grown in the United States. Under this program, novel traits discovered by Yield10 will be deployed in corn by a third-party agriculture company with proven expertise introducing new traits into corn.

  • GlobeNewswire4 months ago

    Yield10 Bioscience Reports Encouraging Results from 2018 Field Tests of C3003 and Announces Advancement of C3003 into Commercial Development for Canola

    Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced encouraging results from the Company’s 2018 Field Tests of C3003, a novel yield trait, in canola, Camelina and soybean. Yield10 is targeting step-changes of 10-20% in the evaluation and development of novel traits to increase seed yield in commercially important crops.  In summary, the C3003 trait produced seed yield increases of up to 11% in the best lines of canola tested. Based on these results, the Company will progress C3003 in canola into the commercial development phase in 2019.

  • GlobeNewswire5 months ago

    Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor

    Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis.

  • What does Yield10 Bioscience Inc’s (NASDAQ:YTEN) Balance Sheet Tell Us About Its Future?
    Simply Wall St.6 months ago

    What does Yield10 Bioscience Inc’s (NASDAQ:YTEN) Balance Sheet Tell Us About Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Yield10 Bioscience Inc (NASDAQ:YTEN), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • GlobeNewswire6 months ago

    Yield10 Bioscience Announces Third Quarter 2018 Financial Results

    WOBURN, Mass., Nov. 08, 2018 -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to achieve step-change improvements in crop yield to enhance.

  • GlobeNewswire7 months ago

    Yield10 Bioscience to Host Webcast of its Third Quarter 2018 Conference Call

    WOBURN, Mass., Oct. 30, 2018 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), a Company developing new technologies to achieve step-change improvements in crop yield to enhance.